From Prediction to Prescription: The Power of Merging Predictive Analytics with GenAI in Enterprises 
Edvantage Group Announces FY2025 Annual Results 
Magnolia Welcomes Tech Pioneer Luc Haldimann as New Board Chairman to Expand Global Growth and AI Strategy 
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Interim Results 
PLN Collaborates with Norwegian and Japanese Stakeholders to Advance High-Integrity Cross-Border Carbon Markets at COP30 Intercept to Announce Second Quarter 2022 Financial Results on August 3, 2022
MORRISTOWN, N.J., July 27, 2022 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company…
Eyenovia Announces Appointment of Ophthalmic Industry Veteran Michael Rowe as Chief Executive Officer and Board Member
Appointment of Mr. Rowe, Eyenovia’s current Chief Operating Officer, maintains continuity while bringing significant ophthalmic…
Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent…
Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat RAG1 Severe Combined Immunodeficiency
WORCESTER, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a…
Neoleukin Therapeutics to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 9, 2022
SEATTLE, July 27, 2022 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), today announced it…
Acasti Pharma Announces Initiation of Pharmacokinetic Study for GTX-101, the Company’s Drug Candidate for the Treatment of Postherpetic Neuralgia
LAVAL, Quebec, July 27, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
Cidara Therapeutics Submits NDA for Rezafungin and Announces License Agreement with Melinta Therapeutics for Commercialization of Rezafungin in the U.S.
Submitted NDA for rezafungin for candidemia and invasive candidiasis to the U.S. FDA on July…
Celularity Announces Treatment of First Patient in Phase 1/2a Clinical Trial for NK Cell Therapy CYNK-101, in Development for the First-Line Treatment of Advanced HER2 Positive Gastric and Gastroesophageal Junction (G/GEJ) Cancers
CYNK-101 is an investigational genetically modified natural killer (NK) cell therapy designed to synergize with…
Nuvectis Pharma, Inc. Announces Approximately $15.9 Million Private Placement
Fort Lee, NJ, July 27, 2022 (GLOBE NEWSWIRE) — Nuvectis Pharma, Inc (Nasdaq: NVCT) (“Nuvectis”…
Lexicon Announces FDA Acceptance of New Drug Application for Sotagliflozin to Treat Heart Failure
NDA supported by SOLOIST-WHF and SCORED Global Phase 3 Program Evaluating Sotagliflozin in Almost 12,000…
Aptose to Present at the Canaccord Genuity 42nd Annual Growth Conference
SAN DIEGO and TORONTO, July 27, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose” or…
Kymera Therapeutics to Report Second Quarter 2022 Results on August 9
WATERTOWN, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage…
Atsena Therapeutics Announces Opening of New Office and Laboratory Space in North Carolina’s Research Triangle
World-class facility supports the company’s growth, and discovery and development of gene therapies for inherited…
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2022 Earnings and Company Updates
CAMBRIDGE, Mass., July 27, 2022 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage…
Kura Oncology to Report Second Quarter 2022 Financial Results
SAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage…
Alimera Sciences Announces Second Quarter 2022 Financial Results
Consolidated Net Product Revenue of $14.6 Million up 36% vs. Second Quarter of 2021 U.S….
Nephros Second Quarter 2022 Financial Results Conference Call
SOUTH ORANGE, NJ, July 27, 2022 (GLOBE NEWSWIRE) — via NewMediaWire — Nephros, Inc.(Nasdaq: NEPH), a leading water technology…
Reviva Pharmaceuticals Provides Update on Clinical Development Pipeline
Enrollment remains on pace for Reviva’s Phase 3 clinical trial for the treatment of schizophrenia…
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022
ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) — Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing…
vTv Therapeutics Announces Paul Sekhri as new President and Chief Executive Officer
HIGH POINT, N.C., July 27, 2022 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (Nasdaq: VTVT), a…